Oncolytics Biotech shares surge 11.00% after-hours after shareholders approve redomiciliation to Nevada and 2026 Incentive Award Plan.

Oncolytics Biotech Inc. surged 11.00% in after-hours trading following the announcement that shareholders approved three key resolutions at a special meeting. The approvals included the company’s redomiciliation from Canada to Nevada, a 2026 Incentive Award Plan, and the continuation from Alberta to British Columbia. The redomiciliation, expected to be finalized by the end of Q1 2026, signals a strategic shift to a U.S. jurisdiction, potentially enhancing regulatory and operational flexibility. The 2026 Incentive Award Plan, contingent on the redomiciliation, aims to attract and retain talent, further supporting clinical development in gastrointestinal cancers. The approvals align with investor optimism around the company’s streamlined governance and strategic focus on accelerating pelareorep’s regulatory pathways. The after-hours rally reflects confidence in these structural changes and their potential to enhance long-term value.